Alnylam Releases 3rd Annual Patient Access Philosophy Report Demonstrating Stable Access to Approved Therapies as Company Enters New Geographies

– Annual Progress Report Highlights Scope of Innovative and Collaborative Initiatives Supporting Accessibility of RNAi Therapies for People Who Can Benefit Around the World –

CAMBRIDGE, Mass., December 21, 2021–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today released its third annual Patient Access Philosophy Report. This report is designed to measure Alnylam’s global progress against its 2017 commitments to ensure broad access to RNAi therapies for those who stand to benefit.

The 2021 Patient Access Philosophy Report summarizes Alnylam’s latest collaborations with payers, providers, regulators, distributors and advocacy partners. Importantly, the report demonstrates Alnylam’s unwavering commitment to innovative access initiatives as the company serves more patients and enters new geographies, which is critical to its P5x25 strategic plan focused on patients, products, pipeline, performance and profitability. This year’s report also highlights how Alnylam has supported patient access to RNAi therapies amid the ongoing global pandemic.

Highlights include:

Supporting patients from clinical development of new therapies to commercialization: Worldwide, more than 2,250 commercial rare disease patients now trust Alnylam’s therapies. Alnylam’s global programs and partnerships educate and enable patients to access education and care, guided by the belief that no patient should have to wait for hope. Through these partnerships, Alnylam has:

  • Has provided access to its therapies to many patients around the world through the establishment of compassionate use and early access programs.

  • Helped provide better access to home administration for all three approved therapies.

  • Ensured that the majority of US commercially insured patients enrolled in Alnylam’s Patient Services Program have little to no out-of-pocket costs.

  • Trained more than 50 patient advocates from 18 European countries in its therapeutic areas.

  • Supported independent genetic testing programs that have reached nearly 59,000 people in the United States, Canada, Brazil and Europe.

Collaborate with more partners globally to define value and support access: Alnylam’s growth in new markets comes with extensive collaboration around value-based care and responsible pricing. Working with local governments, private and public payers, and delivery partners, Alnylam continues to deliver innovative solutions that break down barriers to care, globally. Through these partnerships, Alnylam has:

  • Expanded its global footprint to over 45 markets worldwide.

  • Instituted zero arbitrary price increases worldwide.

  • 98% coverage for ONPATTRO, 94% for GIVLAARI, and 88% for OXLUMO with US commercial and government insurers, including Medicare and Medicaid.

    • For patients enrolled in Alnylam’s Patient Support Program, 73% of ONPATTRO patients, 84% of GIVLAARI patients and 92% of OXLUMO patients have no cost sharing (no direct payment) for the drug.

  • Established 14 new value-based agreements, achieving 43 total VBAs with US payers (ONPATTRO – 19; GIVLAARI – 13; OXLUMO-11).

  • Established availability of ONPATTRO, Alnylam’s first approved treatment, in more than 30 countries in Canada, Europe, the Middle East and Africa (CEMEA) through direct reimbursement or expanded access.

  • Achieved pricing and reimbursement for ONPATTRO and GIVLAARI in the five largest European markets (France, Germany, Italy, Spain, UK) within 20 months of European Commission approval, faster than average marketing of orphan drugs.

  • Increase to three in the number of Asia-Pacific countries where patients have access to Alnylam medicines.

“Over the past 20 years, I have had the privilege of contributing to a team committed to transforming lives through a new class of innovative medicines. Our team has always understood that the science of RNAi therapy is the first step. The ultimate challenge would be to ensure our patients around the world have access to treatment, regardless of their financial situation and outside events,” said John Maraganore, Ph.D., founding president and CEO of Alnylam. My goal as CEO was to ensure that this commitment to our patients always guides Alnylam’s operations. Almost 20 years later, we have quantifiable evidence that he did and still does. As my tenure as CEO draws to a close, I am delighted to see Yvonne Greenstreet leading our growing team at Alnylam to transform the way patient access is designed and approached globally.”

To learn more about Alnylam’s patient access philosophy or download the 2021 report, click here.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into an entirely new class of innovative drugs with the potential to transform the lives of people with rare genetic, cardio-metabolic, infectious liver diseases and central nervous system (CNS)/eye diseases. Based on Nobel Prize-winning science, RNAi therapies represent a powerful, clinically validated approach to treating a wide range of serious and debilitating diseases. Founded in 2002, Alnylam offers a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutic platform. Alnylam’s commercial RNAi therapeutics are ONPATTRO® (patisiran), GIVLAARI® (givosiran) and OXLUMO® (lumasiran), as well as Leqvio® (inclisiran), which is developed and marketed by Alnylam’s partner, Novartis. Alnylam has an extensive pipeline of investigational drugs, including six product candidates in late-stage development. Alnylam performs its “Alnylam P5x25″ strategy to deliver transformative medicines in rare and common diseases to benefit patients worldwide through sustainable innovation and exceptional financial performance, resulting in a leading biotechnology profile. Alnylam is headquartered in Cambridge, MA For more information about our people, science, and pipeline, please visit www.alnylam.com and connect with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211221005749/en/

contacts

Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and media)
617-682-4340

Josh Brodsky
(Investors)
617-551-8276